ALSPW Spineway SAS

Strengthened presence in Europe

Strengthened presence in Europe

Press release        Ecully, July 8, 2024 – 8 a.m.



Spineway continues its sales and marketing efforts in Europe

The Spineway Group, a specialist in innovative implants for the treatment of severe spine disorders, announces that it participated in the , the annual congress of the Spanish Spine Society, held in Malaga in May.

GEER is the annual meeting of spine surgeons in Spain, like the held in Montpellier at the beginning of June.1 Spineway’s participation in these two international congresses allowed the company to develop new training partnerships and to increase its visibility and position in key European markets. At the SFCR Congress, Spineway recruited a new agent to strengthen its presence in the Paris-South and North-West regions, with a view to eventually covering the whole of France.



At GEER, Spineway was present alongside its two distribution partners, the and . Palex is a major player in import and distribution in Spain (€1 billion in revenue). Active in all medical and surgical specialties, it is responsible for expanding sales of Spineway’s arthrodesis ranges in Spain (in particular the VEOS system). Technospine is responsible for distributing the Group’s ESP disc prostheses in Spain. 

During the congress, Stéphane Le Roux, Group CEO, and Fabrice Paccagnella, Global Sales Director, accompanied by members of the sales and marketing team, presented the VEOS and ACIFBOX ranges and the Group’s latest innovations to the Spanish surgical community.

Europe has become the 2nd sales territory since July 2022 (over 50%), thanks to the acquisitions of Distimp in 2021 and Spine Innovations in July 2022, whose products meet the needs of spine surgeons. The next major event for Spineway will be the SILACO Congress in Mexico, from July 24 to 27, which will bring together spine surgeons from Latin and South America.

Spineway plans to continue its expansion in Europe and confirms its aim of becoming a major player in less invasive spine treatments.

Next event:

July 15, 2024 – H1 2024 revenue

July 24 to 27, 2024 – SILACO Congress in Mexico

SPINEWAY IS ELIGIBLE FOR PEA-SME (EQUITY SAVINGS PLANS FOR SMES)

Find out all about Spineway at

This press release has been prepared in both English and French. In case of discrepancies, the French version shall prevail.

Spineway designs, manufactures and markets innovative implants and surgical instruments for treating severe disorders of the spinal column.

Spineway has an international network of independent distributors and derives more than 70% of its revenue from exports.

ISIN: FR001400BVK2 – ALSPW        

Contacts:

SPINEWAY GROUP



Shareholder-services line



Available Tuesday through Thursday



+33 (0)806 706 060
Eligible PEA / PME





ALSPW





Euronext Growth

AELIUM



Finance & Communication







Investor relations



Solène Kennis






1 Press release of June 10, 2024

Attachment



EN
08/07/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Spineway SAS

 PRESS RELEASE

Spineway : 2025 annual results

Spineway : 2025 annual results Ecully, February 17, 2026 – 7:00 p.m. SPINEWAY2025 annual results Revenue up 4%Improved resultsStronger growth potential Condensed consolidated income statement20252024Pro forma* 2024ReportedIn thousands of euros Revenue12,43011,950 11,950Cost of sales-3,783-3,699 -3,699Gross margin 8,6478,250 8,250% of revenue69,6%69,0% 69%Net operating expenses-10,780-10,227 -9,131Of which external expenses-3,967-3,522 -3,646Of which personnel expenses-4,600-4,890 -4,890     Of which other op. income and expenses-1,436-920 -358Of which dep., amort., and provisions-777-895 ...

 PRESS RELEASE

SPINEWAY : Résultats annuels 2025

SPINEWAY : Résultats annuels 2025 Ecully, le 17 février 2026 – 18h30 SPINEWAY Résultats annuels 2025 Un chiffre d’affaires en progression de + 4%Une amélioration des résultatsUn potentiel de croissance renforcé Compte de résultat consolidé résumé20252024Proforma* 2024PubliéEn milliers d'euros Chiffre d'affaires12 43011 950 11 950Coût des ventes-3 783-3 699 -3 699Marge brute8 6478 250 8 250% du CA69,6%69,0% 69%Coûts nets d’exploitation-10 780-10 227 -9 131Dont charges externes-3 967-3 522 -3 646Dont charges de personnel-4 600-4 890 -4 890     Dont autres pdts et ch. d'exploitation-1 43...

 PRESS RELEASE

SPINEWAY : Chiffre d’affaires annuel 2025 de 12,4 ME avec une accéléra...

SPINEWAY : Chiffre d’affaires annuel 2025 de 12,4 ME avec une accélération des ventes au T4 2025 (+34%) Ecully, le 13 janvier 2026 – 18h30 SPINEWAY Chiffre d’affaires annuel 2025 de 12,4 M€ avec une accélération des ventes au T4 2025 (+34%) En milliers d’euros20252024Variation en %CA 1er semestre5 5736 535- 15%CA 2ème semestre6 8575 415+ 27%CA annuel12 43011 950+ 4% Données consolidées non auditées Au dernier trimestre 2025, Spineway, spécialiste des implants innovants pour le traitement des pathologies de la colonne vertébrale (rachis), a bénéficié d’une accélération des ventes sur l...

 PRESS RELEASE

SPINEWAY : 2025 revenue of €12.4 million,  with an acceleration of sal...

SPINEWAY : 2025 revenue of €12.4 million,  with an acceleration of sales in Q4 2025 (+34%) Ecully, January 13, 2026 – 6:30 p.m. SPINEWAY 2025 revenue of €12.4 million, with an acceleration of sales in Q4 2025 (+34%) In thousands of euros20252024Change as a %H1 revenue5,5736,535-15%H2 revenue6,8575,415+27%Full-year revenue12,43011,950+4% Unaudited consolidated data In the final quarter of 2025, Spineway, a specialist in innovative implants for the treatment of severe spine disorders, benefited from an acceleration in sales across all of its markets and the receipt of key account orders d...

 PRESS RELEASE

SPINEWAY : Evolution Surgical distribuera les prothèses discales CP-ES...

SPINEWAY : Evolution Surgical distribuera les prothèses discales CP-ESP et LP-ESP en Australie  Ecully, le 22 octobre 2025 – 8h30 SPINEWAY Evolution Surgical distribuera les prothèses discales CP-ESP et LP-ESP de Spineway en Australie  Spineway, spécialiste des implants innovants pour le traitement des pathologies sévères de la colonne vertébrale (rachis), annonce la conclusion d'un accord avec Evolution Surgical, pour la distribution exclusive de ses prothèses discales ESP en Australie à partir du 25 octobre 2025. Orthotech, l’ancien distributeur sur cette zone, assurera en collaboratio...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch